The first indication that patients with rheumatoid arthritis (RA) produce antibodies to a specific autoantigen was published in 1964 by two Dutch scientists, Nienhuis and Mandema. The exact nature of this antigen, the so-called perinuclear factor, remained unclear for decades. In 1978, the target of seemingly unrelated RA-specific autoantibodies (that is, keratin) was identified. Almost 15 years later, Guy Serre's group convincingly showed that both antigens were identical to the cytokeratin filament-aggregating protein filaggrin (reviewed in \[[@B1]\]). Our own previously published results had shown that the newly made precursor of filaggrin in cultured buccal mucosa cells (that is, profilaggrin) did not react with RA antibodies \[[@B2]\]. This prompted us to consider the possibility that a post-translational modification of filaggrin, absent on newly made profilaggrin, was required for the formation of the antigenic target of these antibodies. Since 1994, we have tested several likely modifications using synthetic peptides. Indeed, citrullination, the enzymatic conversion of peptidylarginine into peptidylcitrulline, turned out to be essential to make peptides reactive with RA autoantibodies. We subsequently developed an enzyme-linked immunosorbent assay with citrullinated peptides and confirmed that the anti-peptidylcitrulline activity was specific for RA \[[@B3]\]. Our further work was directed to the development of the CCP2 test, using cyclic citrullinated peptides (CCPs) selected from random peptide libraries \[[@B4]\].

The discovery of CCP/protein as the most prominent RA-specific antigen had great impact on RA diagnostics and our understanding of RA pathophysiology. The following milestones can be noted (see \[[@B5]\] also).

1\. After decades of intensive research by many groups, a specific diagnostic test for RA had finally been developed. The CCP2 test has a specificity of more than 95%, is very sensitive (\~75%), and is still considered the gold standard in RA autoantibody testing. Since 2010, anti-citrullinated protein antibodies (ACPAs) have been included in the new American College of Rheumatology/European League Against Rheumatism classification criteria for RA.

2\. Recently, an international reference preparation for ACPAs was evaluated by the International Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases \[[@B6]\]. It is available for the scientific community via the Centers for Disease Control and Prevention (Atlanta, GA, USA).

3\. A positive CCP2 test predicts the development of RA, often years before clinical confirmation (reviewed in \[[@B5]\]). It appears that time to RA diagnosis is shorter in patients with high anti-CCP2 titers at enrollment as compared with those with low titers \[[@B7]\].

4\. ACPA-positive RA is characterized by a more severe disease course. Early treatment of ACPA-positive individuals appears to be very effective.

5\. ACPA-negative patients (about 25% of the total RA population) generally display a much milder course of disease. About 35% of such ACPA-negative patients produce anti-carbamylated protein antibodies. Interestingly, the chemical product of carbamylation (that is, lysine converted to homocitrulline) is structurally very similar to citrulline \[[@B8]\].

6\. Specific human leukocyte antigen (HLA) genes (DRB1 shared epitope (SE) alleles) not only are the most important genetic risk factor for RA but also are strongly associated with the production of ACPAs.

7\. The best known environmental risk factor for RA, cigarette smoking, is a risk factor only for ACPA-positive and not for ACPA-negative RA \[[@B9]\]. There is increasing evidence that smoking acts as a trigger for anti-citrulline immunity and does so mainly in the context of certain HLA genes and certain other genetic risk factors.

8\. ACPAs and citrullinated antigens form immune complexes which stimulate the inflammatory process. Continuous production of such immune complexes ultimately results in the chronic inflammation, characteristic for RA (Figure [1](#F1){ref-type="fig"}).

![**Citrullination-related immunity and pathophysiology in rheumatoid arthritis.** In genetically susceptible individuals, an environmental factor may initiate a primary inflammation, which can occur in various tissues, and trigger the immune response to citrullinated proteins (left). The resulting anti-citrullinated protein/peptide antibodies (ACPAs) are distributed through the circulation and may form immune complexes with citrullinated proteins produced in an inflamed synovium, thereby boosting the inflammatory process. This will be associated with the infiltration and activation of neutrophils, macrophages, and lymphocytes; cell death; extracellular DNA trap formation; the activation and release of peptidylarginine deiminases (PADs); *de novo* citrullination; and diversification of the ACPA response. Besides the common inflammation-associated mediators of tissue destruction (not shown), ACPAs and PADs can be directly involved in these processes. HLA, human leukocyte antigen.](ar4458--1){#F1}

Topical aspects of citrullination in rheumatoid arthritis
=========================================================

Autoimmunity against citrullinated autoantigens may be initiated at sites different from the joints. Indeed, evidence has been presented that citrullinated antigens may be produced in lungs during smoking or in gums during infection with bacteria like *Porphyromonas gingivalis* (reviewed in \[[@B10]\]; also, see Figure [1](#F1){ref-type="fig"}). Nevertheless, it has been shown that ACPAs accumulate in synovial fluid of active rheumatic joints as compared with the corresponding serum and that about 25% of synovial IgG-expressing B cells are specific for citrullinated antigens in patients with ACPA-positive RA \[[@B11]\]. These data suggest that ACPAs at least partially are produced in the inflamed joints and that joint-specific citrullinated antigens may diversify and shape the ACPA profile.

Low-avidity ACPAs may be found in both healthy subjects and patients. However, using longitudinal samples obtained from individuals prior to disease onset, ACPA avidity was shown to increase over time until disease onset, after which no further avidity maturation was observed \[[@B12]\]. These data corroborate the notion that ACPAs play an important role in the pathogenesis of RA.

ACPAs represent a heterogeneous group of antibodies recognizing multiple citrullinated peptides and proteins. It remains to be established whether the subclassification based upon ACPA fine-specificity profiles is clinically meaningful.

In the last few years, it also became clear that citrullination may be instrumental to the tissue destruction processes in the synovium. ACPAs were shown to bind to osteoclast surfaces and to induce osteoclast differentiation and subsequent bone resorption \[[@B13]\]. This may explain why ACPA is strongly associated with bone erosion. It is tempting to speculate that the degradation of cartilage is mediated by similar mechanisms. Alternatively, this may be induced by citrullinating enzymes (peptidylarginine deiminases, or PADs), which may citrullinate proteins at the surface of cartilage, inducing their rapid degradation and destabilization of the cartilage.

Next to the antibodies, the citrullination of proteins in the synovium may lead to changes in important physiological processes. Citrullinated fibrinogen and citrullinated collagen type II are more immunogenic and arthritogenic in mouse models of arthritis, and citrullinated fibrinogen activates macrophages more than unmodified fibrinogen \[[@B10]\]. Recently, citrullination of fibronectin was shown to alter synovial fibroblast behavior \[[@B14]\]. Sokolove and colleagues \[[@B15]\] found that fragments of citrullinated proteins can bind to ACPAs and cause activation of macrophages and antigen-presenting cells. Ling and colleagues \[[@B16]\] showed that cell surface calreticulin interacts with the SE to transduce innate immune signals. Citrullination of calreticulin, an abundant process in inflamed synovial tissue, appeared to enhance its affinity for the SE, thus increasing its signaling potency significantly \[[@B16]\]. Interestingly, autocitrullination of PAD4 has been reported to inactivate this enzyme and to enhance its recognition by anti-PAD4 RA sera \[[@B17]\]. Although not all of these data have been confirmed yet by other groups, they strongly suggest that, in addition to ACPA production, protein citrullination can affect the pathophysiology of RA at several levels.

A very interesting phenomenon that links citrullination to inflammation and autoimmunity is the formation of extracellular DNA traps, which is part of the innate immune response \[[@B18]\]. Several inflammatory cells externalize a meshwork of chromatin fibers, containing citrullinated histones, decorated with granule-derived (antimicrobial) proteins. Extracellular trap formation is dependent on citrullination, and proteins associated with these traps may serve as self-antigens \[[@B19]\]. The potential relationship between the anti-citrullinated protein response in RA and citrullination in extracellular traps remains to be investigated.

It is evident by now that the study of citrullination, ACPAs, and citrullinating enzymes becomes more and more important to understand the pathophysiology of RA. It is likely that other modifications of cellular proteins may be intrinsic factors of other autoimmune diseases. Future studies have to prove this idea.
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